INVESTOR RESOURCES
iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS
Corporate Overview
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions. They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure. The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost. The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.
iCHOR at LSI '24
Medline Review Articles
The Latest News
Understanding the Benefits of Rep-Less Thrombectomy
What “Rep-Less” Thrombectomy Means In a traditional model, many thrombectomy procedures rely on having device reps in the room to guide product selection, setup, and troubleshooting. A rep-less approach is significantly different: Devices are designed to be intuitive enough for the team to operate independently, with consistent workflows that do not depend on external personnel. The platform provides an all-in-one,…
A No Compromise Approach to Peripheral Thrombectomy
Innovative new technologies like iSWEEP, embodied in iART and iDVT, clearly demonstrate that peripheral thrombectomy does not have to compromise. No longer do practitioners need to live with the inherent shortcomings of existing aspiration systems, metal draggers, or lytic therapy approaches. Using a proven mechanism of action that mirrors the 60 year surgical Fogarty experience long proven to be effective…